1. A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
- Author
-
Kraveka, Jacqueline, Lewis, Elizabeth, Bergendahl, Genevieve, Ferguson, William, Oesterheld, Javier, Kim, Elizabeth, Nagulapally, Abhinav, Dykema, Karl, Brown, Valerie, Roberts, William, Mitchell, Deanna, Eslin, Don, Hanson, Derek, Isakoff, Michael, Wada, Randal, Harrod, Virginia, Rawwas, Jawhar, Hanna, Gina, Hendricks, William, Byron, Sara, Snuderl, Matija, Serrano, Jonathan, Trent, Jeffrey, and Saulnier Sholler, Giselle
- Subjects
DFMO ,immunotherapy ,maintenance ,neuroblastoma ,precision medicine ,Humans ,Eflornithine ,Pilot Projects ,Induction Chemotherapy ,Retrospective Studies ,Neuroblastoma ,Immunotherapy ,Antineoplastic Agents ,Immunologic Factors ,Genomics ,RNA - Abstract
BACKGROUND: Survival for patients with high-risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapies. AIMS: To study the feasibility and safety of incorporating a genomic-based targeted agent to induction therapy for HRNB as well as the feasibility and safety of adding difluoromethylornithine (DFMO) to anti-GD2 immunotherapy. METHODS: Twenty newly diagnosed HRNB patients were treated on this multicenter pilot trial. Molecular tumor boards selected one of six targeted agents based on tumor-normal whole exome sequencing and tumor RNA-sequencing results. Treatment followed standard upfront HRNB chemotherapy with the addition of the selected targeted agent to cycles 3-6 of induction. Following consolidation, DFMO (750 mg/m2 twice daily) was added to maintenance with dinutuximab and isotretinoin, followed by continuation of DFMO alone for 2 years. DNA methylation analysis was performed retrospectively and compared to RNA expression. RESULTS: Of the 20 subjects enrolled, 19 started targeted therapy during cycle 3 and 1 started during cycle 5. Eighty-five percent of subjects met feasibility criteria (receiving 75% of targeted agent doses). Addition of targeted agents did not result in toxicities requiring dose reduction of chemotherapy or permanent discontinuation of targeted agent. Following standard consolidation, 15 subjects continued onto immunotherapy with DFMO. This combination was well-tolerated and resulted in no unexpected adverse events related to DFMO. CONCLUSION: This study demonstrates the safety and feasibility of adding targeted agents to standard induction therapy and adding DFMO to immunotherapy for HRNB. This treatment regimen has been expanded to a Phase II trial to evaluate efficacy.
- Published
- 2022